Strong advocacy is needed if progress is to be made against tuberculosis.
It was difficult to avoid a sense of despair after last week's Pacific Health Summit, in Seattle, Washington. The meeting — an annual gathering of researchers, public-health policy-makers, drug regulators and heads of non-governmental organizations, industry and funding institutions — was focused this year on tuberculosis (TB). As presentation followed presentation, the overwhelming scale of the challenge became all too evident. The global economic downturn is exacerbating both the burden of the disease and the obstacles to finding resources to cope with it.
About one-third of the world's population carries the bacterium that causes TB, Mycobacterium tuberculosis, and roughly 10% of these people will go on to develop the disease. Because drug courses can last for a year or more, most people do not complete their treatment, and the growth of resistance is therefore inevitable. Strains of M. tuberculosis are now appearing that are resistant not just to the front-line drugs used in initial treatment but also to the second-line drugs used to treat people who have become resistant, as in the case of the 'extensively drug-resistant tuberculosis' first recognized in 2005. As a recent review article dauntingly but appropriately put it, responding to the issue of resistance requires “a comprehensive approach incorporating innovation from the political, social, economic and scientific realms” (M. Jassal and W. R. Bishai Lancet Infect. Dis. 9, 19–30; 2009).
The timescale involved from research to the rolling out of new drugs and biomarkers is alarmingly large.
Happily, there are some signs of progress. The World Health Organization points out that existing drugs and diagnostics can still make a difference if applied properly. And major improvements in tackling the disease would come from a more joined-up approach with the diagnosis and treatment of HIV/AIDS, which often occurs together with TB.
Unhappily, many of these measures require trained staff, well-designed buildings and procedures that minimize the spread of infection — resources that simply aren't available in many regions of the world.
Despite donations of vaccines by industry, price-tiering in poorer regions, progress in clinical trials, advanced market-commitment mechanisms and increases in research funding by organizations such as the US National Institutes of Health, the scale of funding remains dwarfed by the challenges. What progress has been made in research simply clarifies just how inadequate our knowledge is. Researchers have only a basic understanding of how the bacterium affects the various parts of the body, and the heterogeneity of its make-up and behaviour is reflected in the spectrum of progressions from infection to active TB. Furthermore, little is known about how the human body responds to M. tuberculosis infection and the bacterium can mutate up to a thousand times faster as it adapts to antibiotic attack and other stressors.
As Anthony Fauci, head of the US National Institute of Allergy and Infectious Diseases in Bethesda, Maryland, stated at the meeting in his overview of the science, generations of advances in research and technology have bypassed TB research. That is beginning to change, but the timescale involved from research to the rolling out of new drugs and biomarkers is alarmingly large given the immediacy of the threats and the complexity of the organism.
Why hasn't more progress been made? According to Margaret Chan, head of the World Health Organization, the field has been too isolated and inward-looking, and needs to learn lessons from the approach to HIV/AIDS by reaching out and finding highly effective champions. Easily said. But the nine million people who develop active TB every year could only agree that the need to capture the world's imagination and support is urgent.
About this article
Cite this article
Orphan giant. Nature 459, 1034 (2009). https://doi.org/10.1038/4591034a